JS001 in Combination With RC48-ADC in Treatment of HER2-Positive Advanced Malignant Solid Tumors
NCT04280341
·
clinicaltrials.gov ↗
PHASE1
Phase
UNKNOWN
Status
50
Enrollment
OTHER
Sponsor class
Conditions
HER2-Positive Solid Tumors
Interventions
BIOLOGICAL:
RC48-ADC in combinaton with JS001
Sponsor
Peking University
Collaborators
[object Object]